CytomX Therapeutics to Present at Upcoming February Conferences

Core Insights - CytomX Therapeutics, Inc. is a leader in masked, conditionally activated biologics, focusing on localized therapies for cancer treatment [1][3] Group 1: Upcoming Conferences - CytomX management will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, at 4:30 p.m. ET in New York, NY [2] - The company will also present at the World ADC London 2026 on February 25, 2026, at 5:00 p.m. GMT in London, UK [2] Group 2: Company Overview - CytomX is a clinical-stage biopharmaceutical company focused on oncology, developing novel conditionally activated, masked biologics localized to the tumor microenvironment [3] - The company’s pipeline includes therapeutic candidates such as varsetatug masetecan (formerly CX-2051) and CX-801, targeting solid tumors and cold tumors respectively [3] - Varseta-M is designed to target the epithelial cell adhesion molecule (EpCAM), which is highly expressed in tumors but previously undruggable due to normal tissue expression [3] - CX-801 is a masked interferon alpha-2b PROBODY cytokine with potential applications in both immuno-oncology sensitive and insensitive tumors [3] - CytomX has established strategic collaborations with major oncology leaders including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3]